Actively Recruiting

Age: 18Years - 75Years
All Genders
NCT07198230

Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Led by Ting YANG · Updated on 2025-11-18

10

Participants Needed

1

Research Sites

130 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Current exploration of local therapies for large Diffuse Large B-Cell Lymphoma (DLBCL) masses remains in its infancy. This study aims to retrospectively evaluate the safety, efficacy, and tolerability of Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) for treating recurrent and refractory DLBCL masses. It seeks to establish a novel local salvage treatment strategy for such patients while providing preliminary theoretical foundations and clinical data to support future large-scale, multicenter clinical trials.

CONDITIONS

Official Title

Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 75 years
  • Pathologically confirmed diffuse large B-cell lymphoma (DLBCL)
  • Recurrence or resistance after multiple treatments including chemotherapy, immunotherapy, or targeted therapy
  • Presence of at least one bulky lesion 5 cm or larger or confirmed by imaging
  • Lesions have rich blood supply confirmed by CT, MRI, or PET-CT suitable for transarterial therapy
  • Previous positive response to doxorubicin-based therapy
  • ECOG performance status of 2 or less
  • Blood counts, liver, kidney, and coagulation tests within specified safe limits
  • At least one prior DEB-TACE treatment at this institution
Not Eligible

You will not qualify if you...

  • Severe heart, lung, liver, or kidney problems preventing safe treatment
  • Active or uncontrolled serious infections
  • Severe bleeding disorders or coagulation problems
  • Pregnancy, breastfeeding, or planning pregnancy during the study
  • Allergies or contraindications to drug-eluting beads or chemotherapy drugs
  • Psychiatric or cognitive issues that prevent following treatment and follow-up
  • Any other condition the investigator considers unsuitable for participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

The First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, China, 350001

Actively Recruiting

Loading map...

Research Team

X

Xiaoquan ji

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here